EUCTR2019-001807-19-IT进行中（未招募）1 期
An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP) - Open RECLAIM-DCP
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who have completed Study TV50717-CNS-30080 have already met the criteria below:
- •a. Patient ha completed parent Study TV50717-CNS-30080.
- •b. Patient weighs at least 12 kg (26 lb) on day 1 of this study.
- •c. Patient is able to swallow TEV-50717 tablet whole.
- •d. Patient and caregiver/adult are willing to adhere to TEV-50717 regimen and comply with all study procedures.
- •e. Patient is in good general health, as indicated by medical and psychiatric history and physical and neurological examination.
- •f. In the investigator's opinion, the patient and caregiver/adult have the ability to understand the nature of the study and its procedures, and the patient is expected to complete the study as designed.
- •g. For a patient who is a minor, the parent(s)/legal guardian(s) provides written informed consent, and the patient provides assent (in accordance with local regulations). Adult patients (in accordance with local regulations) provide their own written informed consent.
- •h. A caregiver provides written informed consent after being assigned the role by an adult patient or if this role is delegated by the parent/legal guardian of a patient who is a minor.
- •i. Females who are postmenarchal or =12 years of age whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the study (ie, starting at day 1) and for 30 days after last dose of TEV-50717.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will not be randomized/enrolled in this study if they meet any of the following criteria:
- •a. Patient has clinically significant depression at day 1 of this study. Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose.
- •b. Patient has a history of suicidal intent or related behaviors: (i) previous intent to act on suicidal ideation with a specific plan, irrespective of level of ambivalence, at the time of suicidal thought; (ii) previous suicidal preparatory acts or behaviour.
- •c. Patient has a history of a previous actual, interrupted, or aborted suicide attempt.
- •d. Patient has a first-degree relative who has completed suicide.
- •e. Patient who is currently receiving or who has received botulinum neurotoxin (BoNT) in an investigational clinical trial. Note: Patients may be included in the study if they have at least 2 treatments of Food and Drug Administration-approved BoNT at a regular interval (eg, every 3 to 4 months), in reasonably stable dosages and locations (subject to investigator's judgement) to treat lower limb spasticity or dystonia. Food and Drug Administration-approved BoNT is to be defined as an FDA-approved compound, not necessarily an FDAapproved treatment for children. BoNT treatments other than FDAapproved drugs can be submitted to the medical monitor for consideration.
- •f. Patient has received any of the following concomitant medications for dystonia or chorea within the specified exclusionary windows of day of this study: (a) within 3 months: depot neuroleptics; (b) within 30 days: tetrabenazine or valbenazine; (c) within 21 days: reserpine; (d) within 14 days: neuroleptics (oral), typical and atypical antipsychotics, metoclopramide, levodopa, dopamine agonists, and monoamine oxidase inhibitors.
- •g. Patient has received treatment with stem cells, deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation for treatment of abnormal movements or CP, or the patient is not in a stable clinical condition.
- •h. Patient has recent surgical procedure or is anticipated to have a surgical procedure during the study that, in the opinion of the investigator, makes the patient unsuitable for the
- •i. Patient has a severe mental disability or an unstable or serious medical illness (eg, epilepsy) that, in the opinion of the investigator, could jeopardize or would compromise the patient's ability to participate in this study.
- •j. Patient has a QT interval (QTc) corrected for heart rate using Fridericia's formula (QTcF) value >450 msec on 12-lead ECG at day 1 of this study.
- •k. Patients with a history of torsade de pointes, congenital long QT syndrome, bradyarrhythmias, other cardiac arrhythmias, or uncompensated heart failure.
- •l. Patient has evidence of hepatic impairment, as indicated by the following: (a) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5× the upper limit of the normal range (ULN) at day 1 of this study; (b) alkaline phosphatase (ALP) or total bilirubin (Tbil) >2×ULN at day 1 of this study. Note: Patients with Gilbert's syndrome are eligible to participate if approved by the medical monitor. Note: Patients with abnormalities in 2 or more of the following clinical laboratory parameters must be approved for enrollment by the medical monitor: AST, ALT, ALP, and Tbil.
- •m. Patient has evidence of clinically significant renal impairment, indicated by a serum creatinine >1.5×ULN at day 1 of this study.
- •n. Patient has a known aller
研究者
相似试验
进行中（未招募）
1 期
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 20.1Level: LLTClassification code 10068804Term: Athetoid cerebral palsySystem Organ Class: 100000004850EUCTR2019-001807-19-GBTeva Branded Pharmaceutical Products R&D, Inc.185
进行中（未招募）
1 期
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 20.1Level: LLTClassification code 10068804Term: Athetoid cerebral palsySystem Organ Class: 100000004850EUCTR2019-001807-19-PLTeva Branded Pharmaceutical Products R&D, Inc.185
进行中（未招募）
1 期
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyDyskinesia in cerebral palsy (DCP)MedDRA version: 20.1 Level: LLT Classification code 10068804 Term: Athetoid cerebral palsy System Organ Class: 100000004850EUCTR2019-001807-19-ESTeva Branded Pharmaceutical Products R&D, Inc.185
进行中（未招募）
1 期
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral PalsyEUCTR2019-001807-19-DKTeva Branded Pharmaceutical Products R&D, Inc.185
进行中（未招募）
不适用
Open label, long-term safety and tolerability extension study of LCQ908 in subjects with Familial Chylomicronemia Syndrome (FCS).Familial Chylomicronemia Syndrome (FCS) (HLP Type I)MedDRA version: 17.1Level: LLTClassification code 10020607Term: HyperchylomicronemiaSystem Organ Class: 100000004861EUCTR2012-000802-32-GBovartis Pharma Services AG42